Skip to content

VicorderCS NIBP Validation Study to Review The Ability to Capture Blood Pressure Measurements

VicorderCS NIBP Validation Study to Assess Its Ability to Capture Blood Pressure Measurements

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06560034
Enrollment
86
Registered
2024-08-19
Start date
2024-08-15
Completion date
2025-07-14
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Pressure, Cardiovascular Diseases, Hypertension

Brief summary

80 Beats Medical introduces the VicorderCS, the next generation of our Vicorder technology designed to manage hypertension and cardiovascular risks. This advanced diagnostic equipment offers non-invasive collection and computation of a plethora of cardiovascular markers. It is faster, easier to use, and more portable than its predecessor, with enhanced connectivity options for extended marker collection and analysis. These markers enable early diagnosis of cardiovascular disease, ensuring positive patient outcomes. With a strong foundation in numerous published clinical studies, the VicorderCS enhances data collection and analysis capabilities, empowering the research community in developing new drugs and therapeutics. This validation study is purposed to evaluate one of the physiological parameters that is measured by the VicorderCS system, which is Non-invasive Blood Pressure (NIBP) via the common oscillometric cuff-based method.

Detailed description

The VicorderCS will enable medical personnel to conduct Blood Pressure measurement procedures for the evaluation of a participant's cardiovascular health. Clinical Rationale This study will compare the accuracy of the 80 Beats Medical noninvasive blood pressure measurement using the VicorderCS device with that of human observers' readings using the auscultatory method, as required by the applicable ISO standard: Non-invasive sphygmomanometers part 2 - clinical investigation of intermittent automated measurement type1. The study will aim to enroll 120 participants for blood pressure readings using both the VicorderCS and auscultatory method using a calibrated aneroid sphygmomanometer. Design Rationale The VicorderCS blood pressure study will be conducted using consenting participants in Summit County Colorado and designed to be compliant with the requirements within the applicable ISO standard1. Study data, including systolic and diastolic blood pressure readings, will be collected using both the VicorderCS and auscultatory method using a sphygmo-manometer. Proposed Solution 80 Beats Medical has developed the VicorderCS, which is indicated for the non-invasive measurement of blood pressure to detect cardiovascular health risks. Device Description VicorderCS consists of the following components: 1. Vascular Sensor (VCS-VAS-1000) measurement device used with accessories (cuffs and tubes) connected to the device; 2. Data Station (VCS-DAT-1000) for data collection and analysis Platform Data Privacy and Security The VicorderCS application follows industry best practices for data privacy and security, including compliance with applicable laws and regulations such as the General Data Protection Regulation (GDPR) and the Health Insurance Portability and Accountability Act (HIPAA). 80 Beats Medical has implemented technical and organizational measures to safeguard user data against unauthorized access, disclosure, alteration, or destruction, and regularly conducts security audits and risk assessments to identify and mitigate potential threats. 80 Beats Medical has established policies and procedures to ensure that user data is used only for its intended purpose and is not shared with unauthorized parties. There are two data sets that will be recorded during this study. One is the pressure waveforms on all four limbs and the other is the Systolic and Diastolic blood pressure measurement on the left arm. All data on the vascular sensor will be deleted after the test is complete. However, the pressure waveforms will be uploaded to the data station before being deleted. This will be part of an internal data pool for use in perpetuity. Users are provided with transparency and control over their data, including the ability to access, correct, and delete their information. Users can opt out of data collection and sharing, where applicable. Security and privacy of user data are critical to maintaining user trust, and 80 Beats Medical is committed to ensuring the application meets the highest standards for data privacy and security. STUDY OBJECTIVES Primary Objective The objective of this study is to collect blood pressure readings using the VicorderCS device. We will subsequently conduct statistical analysis by comparing to the traditional sphygmomanometer method according to the ISO standard. Secondary Objectives A secondary objective of this study is to collect raw waveform data on the opposite arm, and both ankles in order to optimize analysis capabilities in the future. INVESTIGATIONAL PLAN General Schema of Study Design In this cross-sectional study, we will look at the systolic (Sys) and diastolic (Dia) blood pressure of 120 subjects (ages 18 years or older). The primary hypothesis of this study is that the VicorderCS can detect and analyze blood pressure in an easy-to-use and portable device providing more complete diagnostics at the point of care. Study Device 80 Beats Medical has developed the VicorderCSCS, which is indicated for the non-invasive measurement of blood pressure. Indications for use The VicorderCS Device is indicated for adult patients needing a blood pressure reading.

Interventions

DEVICEVicorderCS

1. Vascular Sensor (VCS-VAS-1000) measurement device used with accessories (cuffs and tubes) connected to the device; 2. Data Station (VCS-DAT-1000) for data collection and analysis

Sponsors

80 Beats Medical
Lead SponsorINDUSTRY

Study design

Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Any gender, in good general health * Must be 18 years old or older, inclusive at enrollment * Must be willing to provide blood pressure measurement * Must be able to read, understand, and willingly sign an Informed Consent Form * Must be able to read, speak and understand English * Must be available to attend one study visit at: please specify exact location.

Exclusion criteria

* Excluding subjects with significantly irregular heart rhythm (e.g. Bigeminy, trigeminy, isolated ventricular premature beat (VPB), atrial fibrillation) or are pregnant * No active email address * Non-English or Spanish- speaking * Unable to read in English.

Design outcomes

Primary

MeasureTime frameDescription
Blood Pressure1 DayA mean difference was measured between the VicorderCS noninvasive blood pressure measurement method and the auscultation method using a Korotkoff sounds device with human observers' readings.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORNitin Vaswani, MD

PI

Participant flow

Recruitment details

Recruitment will be performed using email and a flier. Text of the recruitment emails will contain the following information: * Brief description of the study. * Importance of the proposed research * The study will be conducted entirely at the aforementioned location and last for approximately 40 minutes

Pre-assignment details

As described further in the following section on recruitment methods, participants will be sent an email providing information on the study and providing steps to enroll. Members who respond to recruitment emails will be directed to a link where they can schedule their study time and sign a consent form. They will have the opportunity to contact study personnel with questions if necessary. During "sign up", participants will be taken through a questionnaire to collect relevant information.

Baseline characteristics

Characteristic
Age, Continuous40.2 Years
STANDARD_DEVIATION 16.23
Region of Enrollment
United States
86 Participants
Sex: Female, Male
Female
44 Participants
Sex: Female, Male
Male
42 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 86
other
Total, other adverse events
0 / 86
serious
Total, serious adverse events
0 / 86

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 30, 2026